We discuss the entire lineup to address customers' issues and needs, including SD process, API synthesis, and product manufacture under a sequential system.
Here, we describe our facility and production systems that incorporate SD process to enhance the functions of APIs and drug products.
We present Pharmaceutical solutions, facilities, knowhow, history, and other information on the SD process at Fuji Chemical.
The following drugs and excipients developed by us can contribute to DDS: Neusilin®, Fujicalin®, and F-MELT®.
What's New
Event
Enhancement of solubility and bioavailability
The dissolution and bioavailability of a poorly soluble drug can be dramatically increased by solid dispersion technology. Typically, an amorphous solid dispersion is prepared by dissolving a drug and a polymer in an organic solvent, followed by spray drying.
Improvement of API properties
(particulate design and preparations)
The particle size, bulk density and morphology of APIs can be directly controlled by SD technology to obtain an inhalation powder with particle size of LT 5 microns and powders with excellent compression property and tabletability.
Oily API into powder conversion technology
Our proprietary emulsion stabilizing technology can convert any oily ingredients into powders with a high yield and loading.
Orally disintegrating tablet technology
F-MELT® Technology – Orally disintegrating tablet system allows us to provide a customized excipient specific to your OD tablet that is most suitable for your API. In addition, we provide custom ODT preparations by co-spray drying API and F-MELT® components.